Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience

Analia Rodriguez Garzotto,1 Oliver Heine,2 Matthew Turner,3 Francisco Rebollo Laserna,4 Andreas Lorenz5 1Hospital Universitario 12 de Octubre, Ctra Andalucía, Madrid, Spain; 2Zentralklinikum Suhl, Suhl, 3Sandoz International GmbH, Holzkirchen, Germany; 4Sandoz Farmaceutica SA, Madrid, Spain; 5Frauenarztpraxis, Hildburghausen, GermanyBackground: The purpose of this paper is to report real-world data on the relative effectiveness of a biosimilar erythropoiesis-stimulating agent (ESA; Binocrit®), and other available ESAs for the treatment of chemotherapy-induced anemia.Methods: Data were collected retrospectively from single centers in Spain (n=284) and Germany (n=145). Hemoglobin outcomes, transfusion requirements, and serious drug-related adverse events were assessed for each ESA.Results: Hemoglobin outcomes and transfusion requirements were generally similar in the different ESA treatment groups assessed. No serious drug-related adverse events were recorded in any of the treatment groups.Conclusion: These data confirm the real-world effectiveness and safety of a biosimilar ESA (Binocrit®) for the treatment of cancer patients with chemotherapy-induced anemia.Keywords: erythropoiesis-stimulating agents, chemotherapy-induced anemia, biosimila